<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1993">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407576</url>
  </required_header>
  <id_info>
    <org_study_id>070036</org_study_id>
    <secondary_id>07-M-0036</secondary_id>
    <nct_id>NCT00407576</nct_id>
  </id_info>
  <brief_title>PET Imaging of Brain Amyloid Using [11C]MeS-IMPY</brief_title>
  <official_title>PET Imaging of Brain Amyloid Using [11C]MeS-IMPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid.&#xD;
      The purpose of this study is to test the ability of a research drug to measure amyloid in&#xD;
      brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid&#xD;
      plaques in brain. A substantial body of research indicates that the presence of increased&#xD;
      beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD&#xD;
      including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration.&#xD;
      There are multiple binding sites available on beta-amyloid plaques. Three clearly identified&#xD;
      sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under&#xD;
      development using positron emission tomography (PET) for studying beta-amyloid in clinical&#xD;
      research or drug development are based on Thioflavin-T site, such as [11C]PIB and [11C]SB-13.&#xD;
      Though variously effective, these radioligands have one or more drawbacks with respect to&#xD;
      measuring relative regional beta-amyloid densities. Therefore, we have recently developed&#xD;
      [11C]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more&#xD;
      accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to&#xD;
      evaluate [11C]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of&#xD;
      brain imaging beta-amyloid plaques in AD patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1, 2006</start_date>
  <primary_completion_date type="Actual">November 7, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]MeS-IMPY</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical&#xD;
        exam, ECG, and laboratory tests.&#xD;
&#xD;
        Informed Consent.&#xD;
&#xD;
        AD Patients: Mini-Mental State Examination (score greater than or equal to 10).&#xD;
&#xD;
        AD Patients: Meet NINCDS-ADRDA criteria for probable AD.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Current or prior history of any alcohol or drug abuse.&#xD;
&#xD;
          2. Severe systemic disease based on history and physical exam.&#xD;
&#xD;
          3. Positive result on urine screen for illicit drugs.&#xD;
&#xD;
          4. Laboratory tests with clinically significant abnormalities.&#xD;
&#xD;
          5. Prior participation in other research protocols or clinical care in the last year such&#xD;
             that radiation exposure would exceed the annual limits.&#xD;
&#xD;
          6. Pregnancy or breast feeding.&#xD;
&#xD;
          7. Claustrophobia.&#xD;
&#xD;
          8. Presence of ferromagnetic metal in the body or heart pacemaker.&#xD;
&#xD;
          9. History of brain disease other than Alzheimer's disease.&#xD;
&#xD;
         10. Unable to lay on one's back for the PET/MRI scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001 Dec 15;21(24):RC189.</citation>
    <PMID>11734604</PMID>
  </reference>
  <reference>
    <citation>Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997 Nov;38(11):1818-23.</citation>
    <PMID>9374364</PMID>
  </reference>
  <reference>
    <citation>Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81.</citation>
    <PMID>12368666</PMID>
  </reference>
  <verification_date>November 7, 2008</verification_date>
  <study_first_submitted>December 2, 2006</study_first_submitted>
  <study_first_submitted_qc>December 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>Robert B. Innis, M.D./National Institute of Mental Health</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Brain</keyword>
  <keyword>Neurochemistry</keyword>
  <keyword>Beta-Amyloid Plaques</keyword>
  <keyword>PET</keyword>
  <keyword>MeS-IMPY</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>AD</keyword>
  <keyword>Dementia</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

